Results 51 to 60 of about 62,912 (312)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

ACR Open Rheumatology, 2019
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years.
Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman, Boulos Haraoui   +8 more
doaj   +1 more source

Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

Current Therapeutic Research, 2021
: Background: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory
Samantha Howland, MPharm, J. Jasper Deuring, PhD, Xiaofeng Zhou, PhD, Yan Chen, MD, PhD, Licia MH Mota, MD, Ryan C. Ungaro, MD, MS   +5 more
doaj   +1 more source

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study

European Respiratory Journal
Graphical abstract Overview of the study. ILD: interstitial lung disease; MDA5: melanoma differentiation-associated gene 5; HRCT: high-resolution computed tomography; TOF: tofacitinib; CNI: calcineurin inhibitors; PaO2: arterial oxygen tension; FIO2 ...
Wanlong Wu, B. Guo, Wenjia Sun, Dan Chen, Wenwen Xu, Zhiwei Chen, Yakai Fu, Yan Ye, Xia Lyu, Zhixin Xue, Kaiwen Wang, Jiangfeng Zhao, Cui-Hong Xie, Yi Chen, Chunhua Ye, Min Dai, Wei Fan, Jia Li, Xiaodong Wang, Yu Xue, Weiguo Wan, Li Sun, Huaxiang Wu, Qun Luo, Qian Han, Qiong Fu, Shuang Ye   +26 more
semanticscholar   +1 more source

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

Annals of the Rheumatic Diseases, 2023
Objectives To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis.
R. Fleischmann, D. M. van der Heijde, V. Strand, T. Atsumi, I. McInnes, Tsutomu Takeuchi, Peter C Taylor, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, S. Mukherjee, Ciara O’Shea, D. Saurigny, L. Schifano, Celia Shelton, Julia E Smith, Millie Wang, Reena Wang, S. Watts, M. Weinblatt   +21 more
semanticscholar   +1 more source

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

Rheumatology and Therapy, 2019
Introduction No published studies exist comparing the effectiveness of tofacitinib with other advanced therapies for the treatment of rheumatoid arthritis (RA) in real-world clinical practice.
George W. Reed, Robert A. Gerber, Ying Shan, Liza Takiya, Kimberly J. Dandreo, David Gruben, Joel Kremer, Gene Wallenstein   +7 more
doaj   +1 more source

Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis [PDF]

, 2017
Objectives Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes.
Caslake, Muriel, McCarey, David, McInnes, Iain, Packard, Chris J., Porter, Duncan, Robertson, Jamie, Sattar, Naveed   +6 more
core   +1 more source

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis

Cancers, 2023
Simple Summary Tofacitinib is a relatively novel therapy for immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
C. Bezzio, Marta Vernero, D. Ribaldone, Eleonora Alimenti, G. Manes, S. Saibeni   +5 more
semanticscholar   +1 more source

PMS48 Cost-Effectiveness of Tocilizumab for The Management of Inadequately Responding Rheumatoid Arthritis Patients [PDF]

, 2003
Weiner, LawrencePrimer pla de l'obra. Tres grans paral·lelepípedes de formigó, amb aparença de sarcòfags.Repartits al llarg de l'avinguda.
Hansen, R.N., Best, J.H., Sullivan, S.D., Carlson, J.J.   +3 more
core   +1 more source

Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure

United European Gastroenterology journal
Background and Aims Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report an integrated summary of tofacitinib safety from the completed global UC clinical program (9.2 years maximum tofacitinib exposure ...
J. Panés, G. D’Haens, Bruce E. Sands, S. C. Ng, N. Lawendy, N. Kulisek, Xiang Guo, Joseph Wu, I. Vranic, R. Panaccione, S. Vermeire   +10 more
semanticscholar   +1 more source

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis [PDF]

, 2013
BACKGROUND: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA). There are several randomised clinical trials (RCTs) that have investigated the efficacy and safety of ...
Chan, EWY, Chui, CSL, He, Y, Lau, WCY, Man, KC, Wong, AYS, Wong, ICK, Worsley, AJ   +7 more
core   +3 more sources